Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells

Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dong, Sun, Fei-fan, Wang, Dan, Wang, Tao, Peng, Jing-jing, Feng, Jian-Qiong, Li, Hua, Wang, Chao, Zhou, Dai-jun, Luo, Hong, Fu, Zeng-qiang, Zhang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751222/
https://www.ncbi.nlm.nih.gov/pubmed/32560747
http://dx.doi.org/10.3727/096504020X15925659763817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751222/
https://www.ncbi.nlm.nih.gov/pubmed/32560747
http://dx.doi.org/10.3727/096504020X15925659763817

Ejemplares similares